307 related articles for article (PubMed ID: 21288495)
41. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
[TBL] [Abstract][Full Text] [Related]
43. Clinical consequences of analytical variance and calculation strategy in oral busulfan pharmacokinetics.
Olson MT; Lombardi L; Clarke W
Clin Chim Acta; 2011 Nov; 412(23-24):2316-21. PubMed ID: 21906584
[TBL] [Abstract][Full Text] [Related]
44. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
45. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Clemmons AB; Evans S; DeRemer DL; Awan FT
J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
[TBL] [Abstract][Full Text] [Related]
46. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
[TBL] [Abstract][Full Text] [Related]
47. Beverage intake among preschool children and its effect on weight status.
O'Connor TM; Yang SJ; Nicklas TA
Pediatrics; 2006 Oct; 118(4):e1010-8. PubMed ID: 17015497
[TBL] [Abstract][Full Text] [Related]
48. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
49. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
[TBL] [Abstract][Full Text] [Related]
50. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
51. Overweight/obesity and gastric fluid characteristics in pediatric day surgery: implications for fasting guidelines and pulmonary aspiration risk.
Cook-Sather SD; Gallagher PR; Kruge LE; Beus JM; Ciampa BP; Welch KC; Shah-Hosseini S; Choi JS; Pachikara R; Minger K; Litman RS; Schreiner MS
Anesth Analg; 2009 Sep; 109(3):727-36. PubMed ID: 19690239
[TBL] [Abstract][Full Text] [Related]
52. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
53. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
[TBL] [Abstract][Full Text] [Related]
54. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients.
Griffin SP; Wheeler SE; Wiggins LE; Murthy HS; Hsu JW; Richards AI
Bone Marrow Transplant; 2019 Feb; 54(2):218-225. PubMed ID: 29884851
[TBL] [Abstract][Full Text] [Related]
56. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Poinsignon V; Faivre L; Nguyen L; Neven B; Broutin S; Moshous D; Bourget P; Dufour C; Dalle JH; Galambrun C; Devictor B; Kemmel V; De Berranger E; Gandemer V; Vannier JP; Jubert C; Bondu S; Mir O; Petain A; Vassal G; Paci A
Pediatr Blood Cancer; 2020 Oct; 67(10):e28603. PubMed ID: 32706505
[TBL] [Abstract][Full Text] [Related]
57. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
[TBL] [Abstract][Full Text] [Related]
58. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.
McCune JS; Gooley T; Gibbs JP; Sanders JE; Petersdorf EW; Appelbaum FR; Anasetti C; Risler L; Sultan D; Slattery JT
Bone Marrow Transplant; 2002 Aug; 30(3):167-73. PubMed ID: 12189535
[TBL] [Abstract][Full Text] [Related]
59. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
Mamlouk K; Saracino G; Berryman RB; Fay JW; Pineiro LA; Vance EA; White M; Sandler I; Agura ED
Bone Marrow Transplant; 2005 Apr; 35(8):747-54. PubMed ID: 15750611
[TBL] [Abstract][Full Text] [Related]
60. Busulfan in hematopoietic stem cell transplant setting.
McCune JS; Holmberg LA
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):957-69. PubMed ID: 19611402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]